Fenning RS, Burgert ME, Hamamdzic D, Peyster EG, Mohler ER, Kangovi S, Jucker BM, Lenhard SC, Macphee CH, Wilensky RL (2015)
Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2
J Am Heart Assoc 4:

Johnson JL, Shi Y, Snipes R, Janmohamed S, Rolfe TE, Davis B, Postle A, Macphee CH (2014)
Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial
PLoS ONE 9: e89034

Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL (2014)
Platelet aggregation unchanged by lipoprotein-associated phospholipase A inhibition: results from an in vitro study and two randomized phase I trials
PLoS ONE 9: e83094

Wilensky RL, Macphee CH (2009)
Lipoprotein-associated phospholipase A(2) and atherosclerosis
Curr Opin Lipidol 20: 415

Wilensky RL, Shi Y, Mohler ER, 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH (2008)
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Nat Med 14: 1059

Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ (2003)
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2
Bioorganic & Medicinal Chemistry Lett 13: 1067

Boyd HF, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Pinto IL, Smith SA, Stansfield IG, Theobald CJ, Whittaker CM (2001)
The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2
Bioorganic & Medicinal Chemistry Lett 11: 701

Boyd HF, Flynn ST, Hickey DM, Ife RJ, Jones M, Leach CA, Macphee CH, Milliner KJ, Rawlings DA, Slingsby BP, Smith SA, Stansfield IG, Tew DG, Theobald CJ (2000)
2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2
Bioorganic & Medicinal Chemistry Lett 10: 395

Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD (2000)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group
N Engl J Med 343: 1148

Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM (1999)
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
Biochemical Journal 338 ( Pt 2): 479

Rice SQ, Southan C, Boyd HF, Terrett JA, Macphee CH, Moores K, Gloger IS, Tew DG (1998)
Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor
Biochemical Journal 330 ( Pt 3): 1309

Bell R, Collier DA, Rice SQ, Roberts GW, Macphee CH, Kerwin RW, Price J, Gloger IS (1997)
Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia
Biochemical & Biophysical Research Communications 241: 630

Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH (1996)
Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins
Arterioscler Thromb Vasc Biol 16: 591